Tietze Lysann, Kessler Sonja M
Institute of Pharmacy, Experimental Pharmacology for Natural Sciences, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany.
Cancers (Basel). 2020 May 16;12(5):1261. doi: 10.3390/cancers12051261.
Hepatocellular carcinoma (HCC), the most common primary liver cancer, is challenging to treat due to its typical late diagnosis, mostly at an advanced stage. Therefore, there is a particular need for research in diagnostic and prognostic biomarkers and therapeutic targets for HCC. The use of long noncoding (lnc) RNAs can widen the list of novel molecular targets improving cancer therapy. In hepatocarcinogenesis, the role of the lncRNA , which has been known for more than 30 years now, is still controversially discussed. was described to work either as a tumor suppressor in vitro and in vivo, or to have oncogenic features. This review attempts to survey the conflicting study results and tries to elucidate the potential reasons for the contrary findings, i.e., different methods, models, or readout parameters. This review encompasses in vitro and in vivo models as well as studies on human patient samples. Although the function of in HCC remains elusive, a short outlook summarizes some ideas of using the locus as a novel target for liver cancer therapy.
肝细胞癌（HCC）是最常见的原发性肝癌，由于其典型的诊断较晚，大多处于晚期，治疗具有挑战性。因此，特别需要对HCC的诊断和预后生物标志物以及治疗靶点进行研究。长链非编码（lnc）RNA的使用可以拓宽新型分子靶点的范围，从而改善癌症治疗。在肝癌发生过程中，lncRNA的作用至今已被知晓30多年，但仍存在争议。有人认为它在体外和体内均发挥肿瘤抑制作用，也有人认为它具有致癌特性。本综述试图梳理相互矛盾的研究结果，并试图阐明出现相反结果的潜在原因，即不同的方法、模型或读出参数。本综述涵盖了体外和体内模型以及对人类患者样本的研究。尽管lncRNA在HCC中的功能仍不明确，但简短的展望总结了一些将lncRNA基因座用作肝癌治疗新靶点的想法。
